New MedImmune R&D facility to double its output
This article was originally published in Scrip
Executive Summary
While its search for a new permanent CEO continues, MedImmunehas opened a new 92,000sq ft R&D facility at the Granta Park site in Cambridge, UK, as part of an expansion programme that the company hopes will enable it to significantly increase the number of biological drug candidates it can develop each year.